Vimarsana
Biggest News Aggregation in the World

Page 4 - Cassava Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cassava Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cassava Sciences Today - Breaking & Trending Today

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA - Vimarsana News

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA

NEW YORK, March 27, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor...

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - Vimarsana News

ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between...

IMMINENT SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava ... - Vimarsana News

IMMINENT SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava ...

IMMINENT SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Cassava ...

Cassava Sciences : Corporate Presentation – First Quarter 2024 -March 25, 2024 at 09:36 am EDT - Vimarsana News

Cassava Sciences : Corporate Presentation – First Quarter 2024 -March 25, 2024 at 09:36 am EDT

Corporate Overview First Quarter 2024 Forward-Looking Statements & Other Notices Cassava Sciences is in the business of new drug discovery...

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - Vimarsana News

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials...